Wave Life Sciences (WVE) Liabilities and Shareholders Equity (2016 - 2026)
Wave Life Sciences (WVE) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $583.5 million as the latest value for Q1 2026.
- For Q1 2026, Liabilities and Shareholders Equity rose 102.38% year-over-year to $583.5 million; the TTM value through Mar 2026 reached $1.7 billion, up 42.05%, while the annual FY2025 figure was $638.5 million, 81.29% up from the prior year.
- Liabilities and Shareholders Equity hit $583.5 million in Q1 2026 for Wave Life Sciences, down from $638.5 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $638.5 million in Q4 2025 and bottomed at $146.4 million in Q4 2022.
- Average Liabilities and Shareholders Equity over 5 years is $284.7 million, with a median of $241.4 million recorded in 2025.
- Year-over-year, Liabilities and Shareholders Equity plummeted 32.67% in 2025 and then soared 102.38% in 2026.
- Wave Life Sciences' Liabilities and Shareholders Equity stood at $146.4 million in 2022, then skyrocketed by 87.82% to $274.9 million in 2023, then increased by 28.1% to $352.2 million in 2024, then surged by 81.29% to $638.5 million in 2025, then fell by 8.61% to $583.5 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $583.5 million, $638.5 million, and $241.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.